ClinicalTrials.gg

Program

zibotentan

Also written as “ZD4054”, “Zibotentan” and “Zibotentan/Dapagliflozin”.

Its studies are mostly in Prostatic Neoplasms · Renal Insufficiency, Chronic · Liver Cirrhosis · Kidney Diseases · Renal Insufficiency, led by AstraZeneca.

Furthest: phase 3, since Nov 2, 200723 company-led studies, 2 open or runningNext primary completion: Feb 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca232 open or runningphase 3since Nov 2, 2007Mar 3, 2003Feb 18, 2027phase 3 · NCT06087835
  • Named in AstraZeneca’s own pipeline as zibotentan/dapagliflozin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel and pra-health-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Mar 3, 2003.

  1. Jul 1, 20083 phase 1 studiesNCT00710047, NCT00709553, NCT00713791
  2. Sep 2, 2008Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00745875 · 66 enrolled · Bulgaria, Czech Republic, France and more
  3. Jun 25, 2009Phase 2 study in NeoplasmsNCT00929162 · 120 enrolled · Germany, Italy
  4. Oct 19, 2009Phase 1 study in Advanced Solid MalignanciesNCT00997945 · 15 enrolled · China
  5. Jan 25, 2021Phase 2 study in Renal Insufficiency, ChronicNCT04724837 · 542 enrolled · United States, Argentina, Australia and more
  6. Jul 28, 2021Phase 1 study in Renal Insufficiency, ChronicNCT04991571 · 27 enrolled · United States
  7. Oct 11, 2021Phase 1 study in Renal InsufficiencyNCT05112419 · 12 enrolled · Bulgaria
  8. Aug 16, 2022Phase 1 study in Renal Insufficiency, ChronicNCT05505162 · 24 enrolled · United States
  9. Aug 24, 2022Phase 2 study in Liver CirrhosisNCT05516498 · 205 enrolled · United States, Australia, Austria and more
  10. Oct 4, 2023Phase 3 study in Kidney DiseasesNCT06087835 · 1,835 enrolled · United States, Argentina, Australia and more
  11. Feb 2, 2024Phase 2 study in Liver CirrhosisNCT06269484 · 73 enrolled · United States, Australia, Belgium and more
  12. Nov 29, 2024Phase 1 study in Liver CirrhosisNCT06715670 · 30 enrolled · United States
  13. Apr 17, 2025Phase 2 study in Kidney DiseasesNCT06942910 · 224 enrolled · Russia
  14. Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07404137 · 26 enrolled · United States

Ahead

  1. Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesNCT06087835

TargetBeta

“An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.”NCIt, read by Claude
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule

Other programs on EDNRA

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437
sparsentanruletravere-therapeutics-incphase 49
AtrasentanruleNovartisphase 315
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07404137Renal Insufficiency, Chronic · United States1CompletedApr 2, 202626
NCT06942910Kidney Diseases · Russia2Active, not recruitingSep 26, 2026224
NCT06715670Liver Cirrhosis · United States1CompletedFeb 28, 202530
NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more2CompletedDec 11, 202473
NCT06087835Kidney Diseases · United States, Argentina, Australia and more3Active, not recruitingFeb 18, 20271,835
NCT05516498Liver Cirrhosis · United States, Australia, Austria and more2TerminatedMay 22, 2025205
NCT05505162Renal Insufficiency, Chronic · United States1CompletedJan 10, 202324
NCT05112419Renal Insufficiency · Bulgaria1CompletedDec 15, 202112
NCT04991571Renal Insufficiency, Chronic · United States1CompletedOct 22, 202127
NCT04724837Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedJun 1, 2023542
NCT00997945Advanced Solid Malignancies · China1CompletedSep 201015
NCT00929162Neoplasms · Germany, Italy2TerminatedJun 2011120
NCT00745875Carcinoma, Non-Small-Cell Lung · Bulgaria, Czech Republic, France and more2CompletedJan 201066
NCT00713791Healthy · United States1Completed20
NCT00710047Healthy Volunteers · United Kingdom1CompletedAug 200830
NCT00709553Healthy · Germany1CompletedAug 200812
NCT00672581Hepatic Impairment · Czech Republic1Completed32
NCT00626548Prostatic Neoplasms · United States, Argentina, Australia and more3TerminatedJan 20112,577
NCT00617669Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedMay 20111,494
NCT00554229Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedJul 2010896
NCT00314782Prostatic Neoplasms · United States, Germany, United Kingdom1CompletedMar 200844
NCT00090363Prostatic Neoplasms · United States, Australia, Belgium and more2CompletedDec 2008447
NCT00055471Prostatic Neoplasms · United States2CompletedOct 200522

How it is read

Names in the registry

  • “ZD4054”, 11 entries
  • “Zibotentan”, 4 entries
  • “Zibotentan/Dapagliflozin”, 2 entries
  • “ZD4054 (Zibotentan)”, 2 entries
  • “ZD4054 15 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.